G J Kelloff
Overview
Explore the profile of G J Kelloff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
236
Citations
2626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grossman R, Abel B, Angiuoli S, Barrett J, Bassett D, Bramlett K, et al.
Clin Pharmacol Ther
. 2017 Feb;
101(5):589-592.
PMID: 28187516
The cancer community understands the value of blood profiling measurements in assessing and monitoring cancer. We describe an effort among academic, government, biotechnology, diagnostic, and pharmaceutical companies called the Blood...
2.
Barker A, Sigman C, Kelloff G, Hylton N, Berry D, Esserman L
Clin Pharmacol Ther
. 2009 May;
86(1):97-100.
PMID: 19440188
I-SPY 2 (investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2) is a process targeting the rapid, focused clinical development of paired oncologic therapies...
3.
Christov K, Moon R, Lantvit D, Boone C, Kelloff G, Steele V, et al.
Eur J Cancer
. 2004 Jun;
40(9):1404-11.
PMID: 15177500
In most prostate chemoprevention studies conducted with animal models, the incidence and multiplicity of tumours have been used as endpoints for efficacy. However, the latency of tumours is usually over...
4.
Lieberman R, Brawer M, Crawford E, Labrie F, Miller G, Kelloff G
Prostate Cancer Prostatic Dis
. 2002 Dec;
2(S1):27-33.
PMID: 12496854
Because prostate cancer has a long latency and high incidence, it is a good target for chemoprevention by agents such as retinoids, antiandrogens, antiestrogens, and vitamin D analogs. Phase II...
5.
Sharma S, Ghoddoussi M, Gao P, Kelloff G, Steele V, Kopelovich L
Anticancer Res
. 2002 Mar;
21(6A):3829-37.
PMID: 11911254
One of the approaches in chemoprevention to prevent or delay the progression of precancerous lesions, is to apply chemopreventive agents that can potentially block angiogenesis. A quantitative in vivo angiogenesis...
6.
DAmbrosio S, Wani G, Casto B, Milo G, Kelloff G, Steele V
Anticancer Res
. 2002 Feb;
21(5):3229-35.
PMID: 11848477
Background: Aberrant expression of Ki67, p53 and RARbeta are characteristic of many tumor types including those of the oral cavity. Chemopreventive agents may act by modulating their expression to more...
7.
Mehta R, Bhat K, HAWTHORNE M, Kopelovich L, Mehta R, Christov K, et al.
J Natl Cancer Inst
. 2001 Jul;
93(14):1103-6.
PMID: 11459872
No abstract available.
8.
Sun S, Yue P, Kelloff G, Steele V, Lippman S, Hong W, et al.
Cancer Epidemiol Biomarkers Prev
. 2001 Jun;
10(6):595-601.
PMID: 11401908
The synthetic retinoid, N-(4-hydroxyphenyl)retinamide (4HPR), which is currently being evaluated in clinical trials for cancer prevention and therapy, inhibits the growth of a variety of malignant cells through induction of...
9.
Clifford J, Sabichi A, Zou C, Yang X, Steele V, Kelloff G, et al.
Cancer Epidemiol Biomarkers Prev
. 2001 Apr;
10(4):391-5.
PMID: 11319181
Superficial bladder cancer is a major target for chemoprevention. Retinoids are important modulators of epithelial differentiation and proliferation and are effective in the treatment and prevention of several epithelial cancers....
10.
Hoque A, Lippman S, Boiko I, Atkinson E, Sneige N, Sahin A, et al.
Cancer Epidemiol Biomarkers Prev
. 2001 Apr;
10(3):249-59.
PMID: 11303595
Clinical management of ductal carcinoma in situ (DCIS) remains a challenge because significant proportions of patients experience recurrence after conservative surgical treatment. Unfortunately, it is difficult to prospectively identify, using...